Glycoscience - A new frontier in rational drug design

Acta Pharmaceutica

Volumn 56, Issue 1, 2006, Pages 19-30

  Gornik, Olga ^a,b   Dumiç, Jerka ^a,b   Flögel, Mirna ^a,b   Lauc, Gordan ^a,b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Glycoproteins; Lectins; Therapeutics

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; CARBOHYDRATE; ERYTHROPOIETIN; GALACTOSE; GLUCOSYLCERAMIDASE; GLYCAN; GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOSYLPHOSPHATIDYLINOSITOL; HEPARIN; MUCIN 1; N ACETYLGLUCOSAMINE; N NONYL DEOXYNOJIRIMYCIN; P SELECTIN GLYCOPROTEIN LIGAND 1; PLASMINOGEN ACTIVATOR; PROTEOGLYCAN; SELECTIN; UNCLASSIFIED DRUG; VACCINE;

ANTICOAGULATION; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; GLYCOSYLATION; GRAFT REJECTION; HUMAN; IMMUNITY; INFLAMMATION; LYSOSOME STORAGE DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; REVIEW; VIRUS INHIBITION;

EID: 32844463125     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. C. G. Gahmberg and M. Tolvanen, Why mammalian cell surface proteins are glycoproteins, Trends Biochem. Sci. 21 (1996) 308-311.
2. A. Varki, Biological roles of oligosaccharides: all of the theories are correct, Glycobiology 3 (1993) 97-130.
3. Z. Shriver, S. Raguram and R. Sasisekharan, Glycomics: a pathway to a class of new and improved therapeutics, Nat. Rev. Drug Discov. 3 (2004) 863-873.
4. R. T. Lee, G. Lauc and Y. C. Lee, Glycoproteomics: protein modifications for versatile functions, EMBO Rep. 6 (2005) 1018-1022.
5. G. Lauc and M. Flögel, Glycosylation in stress and disease, Period. Biol. 98 (1996) 279-287.
6. G. Lauc, A. P. Seve, J. Hubert, M. Flögel, W. E. Müller and H. C. Schröder, HnRNP CBP35-CBP67 interaction during stress response and ageing, Mech. Age. Dev. 70 (1993) 227-236.
7. G. Lauc, M. Flögel, B. Diehl-Seifert, H. C. Schröder and W. E. Müller, Identification and purification of a stress associated nuclear carbohydrate binding protein (M(r) 33,000) from rat liver by application of a new photoreactive carbohydrate probe, Glycoconjugate J. 11 (1994) 541-549.
8. K. Barišić, G. Lauc, J. Dumić, M. Pavlović and M. Flögel, Changes of glycoprotein patterns in sera of humans under stress, Eur. J. Clin. Chem. Clin. Biochem. 34 (1996) 97-101.
9. G. Lauc, S. Dabelić, J. Dumić and M. Flögel, Stressin and natural killer cell activity in professional soldiers, Ann. N. Y. Acad. Sci. 851 (1998) 526-530.
10. G. Lauc, J. Peter-Katalinić, S. Dabelić and M. Flögel, Purification and MALDI-MS characterization of a stress-associated glycoprotein from sera of professional soldiers, Biol. Chem. 380 (1999) 443-450.
11. M. Heffer-Lauc, V. Latin, B. Breyer, M. Flögel, W. E. Muller and G. Lauc, Glycoprotein and ganglioside changes in human trophoblasts after exposure to pulsed Doppler ultrasound, Ultrasound Med. Biol. 21 (1995) 579-584.
12. J. Dumić, G. Lauc and M. Flögel, Glycosylation of stress glycoprotein GP62 in cells exposed to heat-shock and subculturing, Glycoconjugate J. 16 (1999) 685-689.
13. J. Dumić, K. Barišić, M. Flögel and G. Lauc, Galectin-3 decreases in mice exposed to immobilization stress, Stress 3 (2000) 241-246.
14. J. Dumić, G. Lauc, M. Hadžija and M. Flögel, Transfer to in vitro conditions significantly influences expression and intracellular distribution of galectin-3 in murine peritoneal macrophages, Z. Naturforsch. 55 (2000) 261-266.
15. J. Dumić, G. Lauc and M. Flögel, Expression of galectin-3 in cells exposed to stress - roles of Jun and NF-kappaB, Cell Physiol. Biochem. 10 (2000) 149-158.
16. S. Dabelić, M. Flögel, G. Maravić and G. Lauc, Stress causes tissue-specific changes in the sialyltransferase activity, Z. Naturforsch. 59 (2004) 276-280.
17. M. Heffer-Lauc, G. Lauc, L. Nimrichter, S. E. Fromholt and R. L. Schnaar, Membrane redistribution of gangliosides and glycosylphosphatidylinositolanchored proteins in brain tissue sections under conditions of lipid raft isolation, Biochem. Biophys. Acta 1686 (2005) 200-208.
18. J. Alper, Searching for medicine's sweet spot, Science 291 (2001) 2338-2343.
19. D. Zopf and G. Vergis, Glycosylation: a critical issue in protein development and manufacturing, Pharm. Visions Spring (2002) 10-14.
20. R. Jefferis, Glycosylation of recombinant antibody therapeutics, Biotechnol. Prog. 21 (2005) 11-16.
21. R. I. Griffiths, N. R. Powe, J. Greer, G. de Lissovoy, G. F. Anderson, P. K. Whelton, A. J. Watson and P. W. Eggers, A review of the first year of Medicare coverage of erythropoietin, Health Care Financ. Rev. 15 (1994) 83-102.
22. T. Misaizu, S. Matsuki, T. W. Strickland, M. Takeuchi, A. Kobata and S. Takasaki, Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin, Blood 86 (1995) 4097-4104.
23. J. Ferrari, J. Gunson, J. Lofgren, L. Krummen and T. G. Warner, Chinese hamster ovary cells with constitutively expressed sialidase antisense RNA produce recombinant DNase in batch culture with increased sialic acid, Biotechnol. Bioeng. 60 (1998) 589-595.
24. K. Mori, R. Kuni-Kamochi, N. Yamane-Ohnuki, M. Wakitani, K. Yamano, H. Imai, Y. Kanda, R. Niwa, S. Iida, K. Uchida, K. Shitara and M. Satoh, Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 SiRNA, Biotechnol. Bioeng. 88 (2004) 901-908.
25. N. Yamane-Ohnuki, S. Kinoshita, M. Inoue-Urakubo, M. Kusunoki, S. Iida, R. Nakano, M. Wakitani, R. Niwa, M. Sakurada, K. Uchida, K. Shitara and M. Satoh, Establishment of FUT8 knock-out Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity, Biotechnol. Bioeng. 87 (2004) 614-622.
26. C. Wrotnowski, Neose targets complex carbohydrate products, Genet. Eng. News 21 (2001) 1-4.
27. E. A. Nutescu, R. K. Lewis, J. M. Finley and G. T. Schumock, Hospital guidelines for use of low-molecular-weight heparins, Ann. Pharmacother. 37 (2003) 1072-1081.
28. M. Bevilacqua, E. Butcher, B. Furie, B. Furie, M. Gallatin, M. Gimbrone, J. Harlan, K. Kishimoto, L. Lasky, R. McEver, J. Paulson, S. Rosen, B. Seed, M. Siegelman, T. Springer, L. Stoolman, T. Tedder, A. Varki, D. Wagner, I. Weissman and G. Zimmerman, Selectins: a family of adhesion receptors, Cell 67 (1991) 233-233.
29. L. A. Lasky, Selectin-carbohydrate interactions and the initiation of the inflammatory response, Annu. Rev. Biochem. 64 (1995) 113-139.
30. G. Thoma, R. Banteli, W. Jahnke, J. L. Magnani and J. T. Patton, A readily available, highly potent E-Selectin antagonist, Angew. Chem. Int. Ed. Engl. 40 (2001) 3644-3647.
31. G. Thoma, J. L. Magnani and J. T. Patton, Synthesis and biological evaluation of a sialyl Lewis X mimic with significantly improved E-selectin inhibition, Bioorg. Med. Chem. Let. 11 (2001) 923-925.
32. J. L. Magnani, The discovery, biology, and drug development of sialyl Lea and sialyl Lex, Arch. Biochem. Biophys. 426 (2004) 122-131.
33. W. M. Abraham, A. Ahmed, J. R. Sabater, I. T. Lauredo, Y. Botvinnikova, R. J. Bjercke, X. Hu, B. M. Revelle, T. P. Kogan, I. L. Scott, R. A. Dixon, E. T. Yeh and P. J. Beck, Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep, Am. J. Respir. Crit. Care Med. 159 (1999) 1205-1214.
34. T. Nemoto, M. J. Burne, F. Daniels, M. P. O'Donnell, J. Crosson, K. Berens, A. Issekutz, B. L. Kasiske, W. F. Keane and H. Rabb, Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure, Kidney Int. 60 (2001) 2205-2214.
35. P. C. Avila, H. A. Boushey, H. Wong, H. Grundland, J. Liu and J. V. Fahy, Effect of a single dose of the selectin inhibitor TBC1269 on early and late asthmatic responses, Clin. Exp. Allergy 34 (2004) 77-84.
36. M. M. Fuster and J. D. Esko, The sweet and sour of cancer: glycans as novel therapeutic targets, Nat. Rev. Cancer 5 (2005) 526-542.
37. R. M. Nelson, O. Cecconi, W. G. Roberts, A. Aruffo, R. J. Linhardt and M. P. Bevilacqua, Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation, Blood 82 (1993) 3253-3258.
38. S. F. Slovin, G. Ragupathi, S. Adluri, G. Ungers, K. Terry, S. Kim, M. Spassova, W. G. Bornmann, M. Fazzari, L. Dantis, K. Olkiewicz, K. O. Lloyd, P. O. Livingston, S. J. Danishefsky and H. I. Scher, Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man, Proc. Natl. Acad. Sci. USA 96 (1999) 5710-5715.
39. S. F. Slovin, G. Ragupathi, C. Fernandez, M. P. Jefferson, M. Diani, A. S. Wilton, S. Powell, M. Spassova, C. Reis, H. Clausen, S. Danishefsky, P. Livingston and H. I. Scher, A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21, Vaccine 23 (2005) 3114-3122.
40. T. Gilewski, G. Ragupathi, S. Bhuta, L. J. Williams, C. Musselli, X. F. Zhang, W. G. Bornmann, M. Spassova, K. P. Bencsath, K. S. Panageas, J. Chin, C. A. Hudis, L. Norton, A. N. Houghton, P. O. Livingston and S. J. Danishefsky, Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial, Proc. Natl. Acad. Sci. USA 98 (2001) 3270-3275.
41. P. J. Sabbatini, V. Kudryashov, G. Ragupathi, S. J. Danishefsky, P. O. Livingston, W. Bornmann, M. Spassova, A. Zatorski, D. Spriggs, C. Aghajanian, S. Soignet, M. Peyton, C. O'Flaherty, J. Curtin and K. O. Lloyd, Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial, Int. J. Cancer 87 (2000) 79-85.
42. R. R. Koganty, M. A. Reddish and B. M. Longenecker, Glycopeptide- and carbohydrate-based synthetic vaccines for the immunotherapy of cancer, Drug Discov. Today 1 (1996) 190-198.
43. P. M. Simon, Pharmaceutical oligosaccharides, Drug Discov. Today 1 (1996) 522-528.
44. M. Fukuda, Possible roles of tumor-associated carbohydrate antigens, Cancer Res. 56 (1996) 2237-2244.
45. R. J. Bitton, M. D. Guthmann, M. R. Gabri, A. J. Carnero, D. F. Alonso, L. Fainboim and D. E. Gomez, Cancer vaccines: an update with special focus on ganglioside antigens, Oncol. Rep. 9 (2002) 267-276.
46. D. Gaucher and K. Chadee, Prospect for an Entamoeba histolytica Gal-lectin-based vaccine, Parasite Immunol. 25 (2003) 55-58.
47. R. Pantophlet, I. A. Wilson and D. R. Burton, Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design, J. Virol. 77 (2003) 5889-5901.
48. A. A. El-Tahawy, The crisis of antibiotic-resistance in bacteria, Saudi Med. J. 25 (2004) 837-842.
49. G. Mulvey, P. I. Kitov, P. Marcato, D. R. Bundle and G. D. Armstrong, Glycan mimicry as a basis for novel anti-infective drugs, Biochimie 83 (2001) 841-847.
50. N. Sharon and I. Ofek, Safe as mother's milk: carbohydrates as future anti-adhesion drugs for bacterial diseases, Glycoconjugate J. 17 (2000) 659-664.
51. D. S. Newburg, G. M. Ruiz-Palacios and A. L. Morrow, Human milk glycans protect infants against enteric pathogens, Annu. Rev. Nutr. 25 (2005) 37-58.
52. J. Bouckaert, J. Berglund, M. Schembri, E. De Genst, L. Cools, M. Wuhrer, C. S. Hung, J. Pinkner, R. Slattegard, A. Zavialov, D. Choudhury, S. Langermann, S. J. Hultgren, L. Wyns, P. Klemm, S. Oscarson, S. D. Knight and H. De Greve, Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin, Mol. Microbiol. 55 (2005) 441-455.
53. T. K. Smith, A. Crossman, J. S. Brimacombe and M. A. Ferguson, Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness, EMBO J. 23 (2004) 4701-4708.
54. E. F. Neufeld, Lysosomal storage diseases, Annu. Rev. Biochem. 60 (1991) 257-280.
55. R. Whittington and K. L. Goa, Alglucerase. A review of its therapeutic use in Gaucher's disease, Drugs 44 (1992) 72-93.
56. R. Whittington and K. L. Goa, Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease, Pharmacoeconomics 7 (1995) 63-90.
57. M. Jmoudiak and A. H. Futerman, Gaucher disease: pathological mechanisms and modern management, Br. J. Haematol. 129 (2005) 178-188.
58. G. A. Grabowski and R. J. Hopkin, Enzyme therapy for lysosomal storage disease: principles, practice, and prospects, Annu. Rev. Genomics Human Genet. 4 (2003) 403-436.
59. T. D. Butters, R. A. Dwek and F. M. Platt, New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases, Adv. Exp. Med. Biol. 535 (2003) 219-226.
60. T. M. Block, X. Lu, F. M. Platt, G. R. Foster, W. H. Gerlich, B. S. Blumberg and R. A. Dwek, Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin, Proc. Natl. Acad. Sci. USA 91 (1994) 2235-2239.
61. X. Lu, A. Mehta, R. Dwek, T. Butters and T. Block, Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion, Virology 213 (1995) 660-665.
62. J. C. Conboy, K. D. McReynolds, J. Gervay-Hague and S. S. Saavedra, Quantitative measurements of recombinant HIV surface glycoprotein 120 binding to several glycosphingolipids expressed in planar supported lipid bilayers, J. Am. Chem. Soc. 124 (2002) 968-977.
63. K. D. McReynolds, A. Bhat, J. C. Conboy, S. S. Saavedra and J. Gervay-Hague, Non-natural glycosphingolipids and structurally simpler analogues bind HIV-1 recombinant Gp120, Bioorg. Med. Chem. 10 (2002) 625-637.
64. J. L. Platt and S. S. Lin, The future promises of xenotransplantation, Ann. N. Y. Acad. Sci. 862 (1998) 5-18.
65. U. Galili, B. A. Macher, J. Buehler and S. B. Shohet, Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1-3)-linked galactose residues, J. Exp. Med. 162 (1985) 573-582.
66. D. K. Cooper, E. Koren and R. Oriol, Oligosaccharides and discordant xenotransplantation, Immunol. Rev. 141 (1994) 31-58.
67. B. E. Samuelsson, L. Rydberg, M. E. Breimer, A. Backer, M. Gustavsson, J. Holgersson, E. Karlsson, A. C. Uyterwaal, T. Cairns and K. Welsh, Natural antibodies and human xenotransplantation, Immunol. Rev. 141 (1994) 151-168.
68. K. R. McCurry, D. L. Kooyman, C. G. Alvarado, A. H. Cotterell, M. J. Martin, J. S. Logan and J. L. Platt, Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury, Nat. Med. 1 (1995) 423-427.